Pulmonx Delays IPO and Reels in $66M Financing
ImplantsPulmonx Delays IPO and Reels in $66M FinancingPulmonx Delays IPO and Reels in $66M Financing
The Redwood City, CA-based company was all set to go public. However, the negative impact of COVID-19 on the market caused Pulmonx to switch gears. Now the firm has raised $66 million to push the commercialization of its minimally invasive treatment for severe emphysema.
Sign up for the QMED & MD+DI Daily newsletter.